Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129318 | 0.93 | TNK2 (1.00) | TNK2CYP2C19 | |
| SCHEMBL1129316 | 0.93 | TNK2 (1.00) | TNK2CYP2C19 | |
| SCHEMBL17855981 | 0.93 | TNK2 (1.00) | TNK2CYP2C19 | |
| SCHEMBL4353349 | 0.89 | TNK2 (1.00) | TNK2CYP2C19 | |
| SCHEMBL20234017 | 0.88 | TNK2 (0.81) | TNK2CYP2C19 | |
| SCHEMBL4358195 | 0.85 | TNK2 (1.00) | TNK2CYP2C19 | |
| SCHEMBL4358200 | 0.85 | TNK2 (1.00) | TNK2CYP2C19 | |
| SCHEMBL20362849 | 0.83 | TNK2 (0.77) | TNK2CYP2C19 | |
| SCHEMBL4370276 | 0.83 | TNK2 (1.00) | TNK2CYP2C19 | |
| SCHEMBL4370274 | 0.83 | TNK2 (1.00) | TNK2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-21 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295129-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | TNK2 2/4885CYP2C19 4665/4885 |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | TNK2 3/4885CYP2C19 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.